Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc is experiencing significant commercial momentum, bolstered by new agreements with notable healthcare institutions such as the Spine Institute of Louisiana and Scripps Health, which enhances the company's market presence. The company achieved a remarkable 132% year-over-year growth in scans for the second quarter and anticipates sustained growth through year-end, indicating strong demand for its Nociscan platform. Additionally, Aclarion's revenues for the quarter reached $19,300, reflecting a 76% year-over-year increase, suggesting a positive trajectory for the company's financial performance despite falling slightly short of initial forecasts.

Bears say

Aclarion Inc's financial outlook is hindered by several fundamental risks, including slower than anticipated traction with payers and increasing marketing and administrative expenses, which are contributing to the revised FY25 EPS estimate of $(15.08), a decline from the previous $(14.10). Additionally, substantial risks to the company's future performance include balance sheet and liquidity issues, potential regulatory approval challenges, and difficulties in commercialization and reimbursement strategies. Overall, the combination of these factors presents significant concerns regarding Aclarion's ability to achieve sustained revenue growth and navigate competitive pressures in the healthcare technology sector.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Nov 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.